omniture
logo
Search
迪哲医药
Media Room

Latest News

rss

Dizal's Rapidly Evolving Oncology Pipeline to Make Waves at 2023 ASCO Meeting

Topline Results from Pivotal Studies of Sunvozertinib and Golidocitinib Selected for Oral Presenta...

2023-04-27 07:20 2126

Dizal Announces China CDE Acceptance of New Drug Application for Sunvozertinib for Platinum-Pretreated NSCLC Patients with EGFR Exon20ins Mutations

SHANGHAI, Jan. 10, 2023 /PRNewswire/ -- Dizal (SHEX: 688192) today announced that the Center for Dr...

2023-01-10 17:03 2344

Dizal Announces Sunvozertinib Meets Primary Endpoint in its First Pivotal Study in Platinum-Pretreated NSCLC Patients with EGFR Exon20ins Mutations at 2022 ESMO

* The confirmed objective response (cORR), as assessed by blinded independent central review (BIC...

2022-09-05 22:49 2621

Dizal Announces Positive Phase I Clinical Trial Results for DZD1516 in Treating HER2 Breast Cancer at 2022 ESMO

PARIS, Sept. 5, 2022 /PRNewswire/ -- Dizal reported the promising safety and pharmacokinetic data f...

2022-09-05 22:39 2545

Dizal to Demonstrate the Strength and Rapid Acceleration of its Clinical Portfolio at ASCO 2022

Sunvozertinib (DZD9008) shows superior efficacy in NSCLC patients harboring EGFR exon 20 insertion ...

2022-05-27 18:00 1745

Dizal Announces New Data from the Phase I/II Study of Golidocitnib in Refractory or Relapsed Peripheral T Cell Lymphoma Selected for Oral Presentation at 2022 EHA Annual Meeting

SHANGHAI, May 13, 2022 /PRNewswire/ -- Dizal (SSE: 688192) will present the data from an ongoing ph...

2022-05-13 19:09 2697

FDA Grants Breakthrough Therapy Designation for Dizal Pharmaceutical's DZD9008 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR Exon20 Insertion

SHANGHAI, Jan. 27, 2022 /PRNewswire/ -- Dizal Pharmaceutical Co., Ltd. (SHEX:688192) ("Dizal"), tod...

2022-01-27 21:15 3676
12